Borrowed Science / Essential Equivalence
Borrowed Science refers to the practice of relying on existing, published scientific literature to substantiate health and wellness claims, rather than a company funding its own proprietary randomized-controlled-trials (RCTs). This is the primary legal defense mechanism and cost-saving strategy used by functional beverage startups to satisfy the ftc’s requirement for competent-and-reliable-scientific-evidence (CRSE).
However, the FTC only permits this practice if the marketed product achieves Essential Equivalence with the product tested in the cited literature.
The Criteria for Essential Equivalence
To be considered essentially equivalent, the consumer product must contain:
- Identical active ingredients.
- The exact same form and route of administration.
- The exact same dosage as the clinical study.
Furthermore, if a brand adds additional ingredients to the formulation (such as flavorings, preservatives, or other functional compounds), it must possess reliable scientific evidence demonstrating that the new formulation does not impede or inhibit the effectiveness of the primary active ingredients.
The Tension with Beverage Economics
The strict requirement for essential equivalence creates a massive hurdle for the beverage industry, directly contributing to the clinical-substantiation-gap.
To legally use “borrowed science,” a beverage must match the clinical dosage of the cited study. However, clinical doses of botanical extracts and adaptogens are often:
- Economically Unviable: Including clinical doses drastically increases the Cost of Goods Sold (COGS), ruining standard beverage margins.
- Organoleptically Disastrous: High doses of functional ingredients often introduce severe bitterness, astringency, or off-notes, ruining the taste profile of the drink.
Consequently, brands face a dilemma: under-dose the product to maintain taste and margins (risking FTC enforcement for unsubstantiated claims), or dose at clinical levels and absorb the financial and sensory penalties.